This trial is evaluating whether F18-DCFPyL will improve 1 primary outcome and 2 secondary outcomes in patients with Carcinoma. Measurement will happen over the course of Baseline, post ablation, disease progression.
This trial requires 50 total participants across 1 different treatment group
This trial involves a single treatment. F18-DCFPyL is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The strong correlations between tumor size and F18-dcfpyl uptake suggest that F18-dcfpyl might be a useful tool for assessing tumor response at early time points. However, further studies are needed to determine whether F18-dcfpyl PET might have limited role in predicting tumor response in patients receiving chemotherapy after surgery." - Anonymous Online Contributor
"The common side effects of f18-dcfpyl were generally mild. The most common side effect was headache. Other common side effects included fatigue, dizziness, nausea, vomiting, and diarrhea. Patients should report all side effects so they can be evaluated and treated appropriately." - Anonymous Online Contributor
"Data from a recent study shows that the F18-dcpyl PET scan was significantly superior to the patient's history and physical examination for predicting survival after resection for HCCA. The authors concluded that this imaging modality may be useful in identifying candidates for liver transplantation who might benefit from an aggressive surgical approach." - Anonymous Online Contributor
"The average age at diagnosis of hepatocellular carcinoma was 61.5 years (average +/-SD=13.8, range = 27-87 years). This is consistent with the general population incidence of HCC and roughly time period of expected occurrence for HCC in the United States. Findings from a recent study suggest that risk factors for HCC differ by tumor site." - Anonymous Online Contributor
"Findings from a recent study have implications for routine follow-up care of patients with HCC as well as clinical trial design. A high preoperative serum AFP level is an independent prognostic parameter for HCC. Findings from a recent study suggest that this parameter should be incorporated into future staging criteria." - Anonymous Online Contributor
"The FDA has approved [(18)F]FDG for PET imaging of tumors. DcfpyL is a novel molecule for use in PET imaging of non-neoplastic disease states and in particular for use in imaging tumors. This compound reflects expression of the MUC4 mucin gene product and thereby may serve as a surrogate marker for MUC4 overexpression. In addition, the drug's labeling properties make it advantageous in double-labeling studies where tumor markers and their analogs are used to image tumors and their metastases. (ClinicalTrials.gov Identifier: NCT00419018." - Anonymous Online Contributor
"Hepatic metastases are very rare and can be clinically and radiographically detected within 6 months after liver transplantation. Yet, some patients with an initial negative CT scan remain free of tumor progression for up to 10 years. The risk factors for early liver recurrence must now be clearly defined." - Anonymous Online Contributor
"The most common cause of hepatocarcinoma is chronic liver disease secondary to viral hepatitis B or chronic alcoholic cirrhosis. In addition to this, chronic cholestasis and certain congenital disorders such as hereditary hemochromatosis may also increase the risk of hepatocarcinoma." - Anonymous Online Contributor
"The incidence of HCC in these groups was 1 per 100,000 persons and 0.6 per 100,000 persons, respectively. For both groups, the underlying cirrhosis had a much higher risk than for the general population." - Anonymous Online Contributor
"Carcinoma, hepatocellular (HCC) is a disease of the liver and is thought to be caused by accumulation of mutated hepatocytes. The risk factors for HCC are obesity, alcohol intake, hepatitis B and C infection, non-alcoholic fatty liver disease, iron overload, diabetes mellitus, and chronic inflammation." - Anonymous Online Contributor
"Findings from a recent study of this study support the theory that F18-dcfpyl can be used alone to treat patients with advanced hepatocellular carcinoma. However, when administered in combination with other drugs, F18-dcfpyl increases the efficacy and reduces toxicity. Thus, we would recommend combining F18-dcfpyl with other drugs to treat patients with advanced hepatocellular carcinomas." - Anonymous Online Contributor